Endpoints News webinar — “Pilots to Production: AI across R&D, Safety, Regulatory, and Clinical” (IBM-sponsored).
Endpoints News webinar — “Pilots to Production: AI across R&D, Safety, Regulatory, and Clinical” (IBM-sponsored). Panel: Sudhir Saxena (Co-Founder & CTO, GNQ Insilico), Deva Ramachandran (Partner, AI & Automation Practice Leader, IBM Consulting), Stuart Pyle (Partner, Life Sciences R&D, IBM). GNQ highlights (Sudhir) Framed the regulatory tailwind first: recent FDA guidance that mechanistically justified evidence […]
IBM’s Quantum AI for Precision Medicine Powered by GNQ Insilico
IBM Consulting is offering a targeted personalized therapy solution, built on GNQ Insilico’s explainable, auditable causal AI (QBRM) with a multimodal Patient 360 (BioAvatar/BioLens) platform, to provide a real-time, pathway-level biological model of each individual patient to accelerate early safety signal detection, precision oncology decision support, regulator-ready evidence for DSMB/FDA workflows, and in silico trial […]
GNQ Insilico Plans to Accelerate Precision Medicine and Clinical AI Adoption Across Drug Development and Patient Care
The new service offering combines GNQ Insilico’s Causal AI Drug Assessment, Drug Simulation, and Digital Twin platforms with IBM’s consulting and hybrid cloud expertise. SAN JOSE, Calif.–(BUSINESS WIRE)–GNQ Insilico, Inc. (GNQ), a precision medicine TechBio company, today announced a collaboration with IBM aimed to help healthcare and life sciences organizations accelerate the adoption of personalized, […]
GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)
IB Acquisition Corp. Mon, March 16, 2026 at 1:45 PM EDT 12 min read BOCA RATON, FL AND TORONTO, ONTARIO, March 16, 2026 (GLOBE NEWSWIRE) — GNQ Insilico Inc. (“GNQ” or the “Company”), a corporation formed under the federal laws of Canada, and IB Acquisition Corp. (Nasdaq: IBAC) (“IBAC”), a Nevada special purpose acquisition […]
FDA shifts 60-year default: One pivotal clinical trial is now the default for drug approval – replacing the two-trial requirement
GNQ INSILICO – COMPETITIVE ADVANTAGE Where Causal Biology Meets Clinical Precision GNQ’s pathway-driven platform doesn’t just predict – it also explains. By modeling the biological mechanisms that determine patient outcomes, we deliver what the new regulatory era demands: one definitive trial, designed right from the start. GNQ INSILICO – COMPETITIVE ADVANTAGE Improved Prediction Accuracy […]
GNQ Insilico Secures MindLab, an Award Winning Pharma Company, as a Client for its Drug Assessment Platform
GNQ Insilico’s Quantum-enhanced and AI-powered Platform to Accelerate Development of MindLab’s Novel Pain Management Therapy PLEASANTON, CA, UNITED STATES, October 30, 2025 /EINPresswire.com/ — GNQ Insilico Inc., a pioneer in quantum-enhanced AI drug development, is pleased to announce a strategic partnership with MindLab, LLC to deploy its newly launched Drug Assessment Platform (DAP) to accelerate […]
GNQ Insilico Launches Revolutionary AI-Driven Assessment Platform to Transform Precision Medicine and Drug Development
Multi-Agentic AI Platform Powered by Proprietary Systems Biology Engine Delivers Personalized Therapy Optimization and Investment Risk Assessment PLEASANTON, CA, UNITED STATES, September 10, 2025 /EINPresswire.com/ — GNQ Insilico Inc. (“GNQ” or “the Company”), a pioneering TechBio firm leveraging exponential technologies for precision medicine, announces the official launch of its groundbreaking deep tech Drug Assessment Platform […]
GNQ Insilico Unveils Multi-Pathway Therapeutic Formulation for ALS Leveraging proprietary Drug Assessment Platform
GNQ Insilico, Inc. (“GNQ” or “the Company”), a cutting-edge TechBio platform company, announced results from its proprietary Drug Assessment Platform. GNQ’s platform represents a breakthrough in computational drug development and due diligence, providing investors and pharmaceutical partners with unprecedented insights into multi-pathway therapeutic optimization. To demonstrate the platform’s transformative capabilities, GNQ has developed a novel, […]
GNQ’s Drug Assessment Platform Enhances Non-Small Cell Lung Cancer Treatment by Extending Efficacy Beyond Universal Resistance Barrier
GNQ Insilico, Inc. (“GNQ” or “the Company”), a TechBio platform company, demonstrated the advanced capabilities of its AI-powered Drug Assessment Platform in addressing critical treatment optimization challenges for patients with Non-Small Cell Lung Cancer (NSCLC). NSCLC remains the leading cause of cancer-related mortality, representing 85% of all lung cancer cases[1]. Patients face significant treatment challenges […]
GNQ presents at Quantum Rising Conference alongside Deloitte & IBM Quantum
Sudhir Saxena, Chief Technology Officer of GNQ Insilico, Inc. (GNQ), was invited by Deloitte Consulting to present GNQ’s multi-omics approach to personalized medicine through AI-powered digital twins at the Quantum Rising Conference held on December 14 and 15 in Atlanta, Georgia (hosted by the National Quantum Literacy Network). At the Quantum Rising conference, Saxena was […]